Results 41 to 50 of about 918 (92)

The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion. [PDF]

Adv Ther
Tafuto S, Lastoria S, Panzuto F, Antonuzzo L, Campana D, Cingarlini S, Cives M, Ferone D, Filice A, Giuffrida D, Maccauro M, Partelli S, Fazio N.   +12 more
europepmc   +1 more source

Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade. [PDF]

Front Nucl Med
Haugh KN, Sanwick AM, Chaple IF.
europepmc   +1 more source

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report. [PDF]

Front Endocrinol (Lausanne)
Gil Dos Santos S, Calheiros R, Oliveira J, Santos AP, Souteiro P.   +4 more
europepmc   +1 more source

Blood-based transcriptomic biomarkers for response to [¹⁷⁷Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors. [PDF]

EJNMMI Res
Sung H, Bae S, Suh M, Choi H, Im HJ, Cheon GJ, Kang KW.   +6 more
europepmc   +1 more source

Assessment of Early Cardiotoxicity and Cardiac Dysfunction of Radioligand Therapy in Patients with Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Jóźwik-Plebanek K, Saracyn M, Kołodziej M, Mądra W, Durma AD, Dziuk M, Balcerska Z, Janiak K, Gniadek-Olejniczak K, Kamiński G.   +9 more
europepmc   +1 more source

Multifactorial analysis of radiochemical purity in high-activity ¹⁷⁷Lu-labeled theranostics: impact of precursor source, ¹⁷⁷Lu form, and production parameters. [PDF]

EJNMMI Radiopharm Chem
Hunt W, Long M, Kamil U, Kellapatha S, Noonan W, Roselt PD, Papa N, Emmerson B, Hofman MS, Haskali MB.   +9 more
europepmc   +1 more source

Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. [PDF]

EJNMMI Res
Herr FL, Dascalescu C, Fusch V, Smith C, Ebner R, Zacherl MJ, Eckenweber F, Klimek K, Auernhammer CJ, Spitzweg C, Ricke J, Heimer MM, Cyran CC, Werner RA, Sheikh GT.   +14 more
europepmc   +1 more source

Challenges and Opportunities in Radioligand Therapy. [PDF]

J Nucl Med Technol
Currie GM, Bailey DL.
europepmc   +1 more source

Correction to: Safety and dosimetry of [¹⁷⁷Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. [PDF]

Eur J Nucl Med Mol Imaging
Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, Wan S, Ceraulo A, Kluczewska-Galka A, Gámez-Cenzano C, States LJ, El Khouli R, Aimone P, Perraud K, Kollar G, Khanshan F, Blumenstein L, Brouri F, Giraudet AL.   +18 more
europepmc   +1 more source

Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy. [PDF]

Cancers (Basel)
Laetsch TW, States LJ, Lazow MA, Chauhan A.   +3 more
europepmc   +1 more source